MRSA was once primarily a problem in hospitals, but is a growing problem in communities around the country now. Related StoriesCleaning patient areas with combination of chemicals and UV light cuts transmission of superbugsCoating implants with cells plasminogen activator can prevent biofilm-related infectionsPlymouth University and Ingenza partner to build up efficient, scalable microbial creation system for epidermicinMatthew J. Kuehnert, MD, and colleagues collected samples from 10 nearly, 000 individuals in the 2001-2002 National Health insurance and Nutritional Examination Survey, a representative sample of the U.S. Population. One-third were found to be colonized with staph Nearly..
Alkermes’ ALKS 5461 drug gets FDA Fast Track status for main depressive disorder Alkermes plc today announced that the U.S. Food and Drug Administration has granted Fast Track position for ALKS 5461 for the adjunctive treatment of main depressive disorder in individuals with an inadequate response to regular therapies. Fast Monitor is a process designed to facilitate the development, and expedite the review of drugs to take care of serious conditions and with the potential to handle an unmet medical want. ‘We are really pleased to have already been conferred Fast Track status for ALKS 5461 as we believe that ALKS 5461 may represent a significant option for the treating major depressive disorder,’ said Elliot Ehrich, Chief Medical Officer of Alkermes.